Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.
Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi
UK actor and TV personality Nadia Sawalha is spearheading a fundraising effort to launch an appeal against the recent rejection of a breast cancer therapy by cost-effectiveness agency NICE.
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer.